We wish to congratulate Crowe et al. (2023) on their recent publication exploring the experience of psilocy-bin treatment. This paper was published a week after the Australian Therapeutic Goods Administration (TGA, 2023) approved the prescription of psilocybin for treatment-resistant depression by authorised psychia-trists under strict controls, acknowledging that patients may be vulnerable during ‘psychedelic- assisted psycho-therapy’. In Australia, the practice of psychotherapy is unregulated, undervalued, rarely provided in any form in public mental health settings, and often conf lated with subsidized brief psychological therapies in primary care (Lakeman, 2021). The medically sanctioned therapeutic use of psychedelics and empathogens may well ref lect a paradigm shift in how pharmacological treatments are viewed, and perhaps more importantly cement the im-portance of psychotherapy in the process of treatment…